Daniel Van Langenberg
Overview
Explore the profile of Daniel Van Langenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu N, Lee T, Tassone D, Vogrin S, Phan S, Wu D, et al.
Intern Med J
. 2024 Sep;
54(11):1856-1866.
PMID: 39234975
Background: Thiopurine co-therapy with anti-tumour necrosis factor-alpha (anti-TNFα) agents is associated with higher anti-TNFα drug levels and reduced immunogenicity in inflammatory bowel disease (IBD). Aims: We aimed to evaluate the...
2.
Srinivasan A, Van Langenberg D, De Cruz P, Segal J, Vasudevan A, Upton R
BioDrugs
. 2024 Aug;
38(5):691-702.
PMID: 39168947
Background: The optimal infliximab dose intensification strategy to address loss of response associated with subtherapeutic infliximab trough levels remains uncertain, as does whether post-intensification trough and treatment targets should influence...
3.
Dutt K, Srinivasan A, Van Langenberg D
BioDrugs
. 2022 Aug;
36(5):639-644.
PMID: 35960446
Background: Despite growing awareness of the nocebo effect, few studies have evaluated the nocebo effect using combined assessment of patient-reported outcome measures (PROMs), clinical indices, and objective biomarkers in inflammatory...
4.
Barnes A, Ooi S, Lynch K, Parthasarathy N, Bishara M, Gounder M, et al.
Dig Dis Sci
. 2022 Jun;
68(3):889-896.
PMID: 35687221
Background: The thiopurine medications are well established in the treatment of inflammatory bowel disease (IBD). There is significant variation in levels of toxic and therapeutic metabolites. Current data from small...
5.
Srinivasan A, Gilmore R, Van Langenberg D, De Cruz P
Therap Adv Gastroenterol
. 2022 Feb;
15:17562848211070940.
PMID: 35126667
Introduction: Anti-tumor necrosis factor (TNF) dose intensification represents an effective method of overcoming secondary loss of response (LOR); however, a subset of patients may not respond (tertiary non-response), or fail...
6.
De Gregorio M, Lee T, Krishnaprasad K, Amos G, An Y, Bastian-Jordan M, et al.
Clin Gastroenterol Hepatol
. 2021 Aug;
20(6):1306-1314.
PMID: 34389484
Background & Aims: Higher anti-tumor necrosis factor-α (TNF) drug levels are associated with improved clinical healing of Crohn's perianal fistulas. It is unclear whether this leads to improved healing on...
7.
Chauhan A, Apostolov R, Van Langenberg D, Garg M
Intern Med J
. 2021 Feb;
51(1):106-110.
PMID: 33572016
Faecal microbiota transplantation (FMT) is reportedly effective and safe for the management of recurrent or refractory Clostridioides difficile infection (CDI), yet real-world data of outcomes of FMT in Australia are...
8.
Srinivasan A, Van Langenberg D, De Cruz P
Inflamm Bowel Dis
. 2021 Feb;
27(6):e69.
PMID: 33570129
No abstract available.
9.
Nicolaides S, Vasudevan A, Van Langenberg D
Aliment Pharmacol Ther
. 2020 Oct;
52(10):1619-1620.
PMID: 33085986
No abstract available.
10.
Haifer C, Srinivasan A, An Y, Picardo S, Van Langenberg D, Menon S, et al.
Med J Aust
. 2020 Oct;
214(3):128-133.
PMID: 33070332
Objective: To examine whether non-medical switching of patients with inflammatory bowel disease (IBD) from originator infliximab to a biosimilar (CT-P13, Inflectra) is safe and clinically non-inferior to continued treatment with...